|Application ||FC, WB|
|Calculated MW||H=55 KDa|
|Other Names||Erythropoietin receptor, EPO-R, EPOR|
|Target/Specificity||This EPOR antibody is generated from a rabbit immunized with a KLH conjugated synthetic peptide between 470-504 amino acids from the C-terminal region of human EPOR.|
|Format||Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein A column, followed by peptide affinity purification.|
|Storage||Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.|
|Precautions||EPOR Antibody (C-term) is for research use only and not for use in diagnostic or therapeutic procedures.|
|Function||Receptor for erythropoietin. Mediates erythropoietin- induced erythroblast proliferation and differentiation. Upon EPO stimulation, EPOR dimerizes triggering the JAK2/STAT5 signaling cascade. In some cell types, can also activate STAT1 and STAT3. May also activate the LYN tyrosine kinase.|
|Cellular Location||Cell membrane; Single-pass type I membrane protein|
|Tissue Location||Erythroid cells and erythroid progenitor cells. Isoform EPOR-F is the most abundant form in EPO-dependent erythroleukemia cells and in late-stage erythroid progenitors Isoform EPOR-S and isoform EPOR-T are the predominant forms in bone marrow. Isoform EPOR-T is the most abundant from in early- stage erythroid progenitor cells|
Provided below are standard protocols that you may find useful for product applications.
Receptor for erythropoietin. Mediates erythropoietin- induced erythroblast proliferation and differentiation. Upon EPO stimulation, EPOR dimerizes triggering the JAK2/STAT5 signaling cascade. In some cell types, can also activate STAT1 and STAT3. May also activate the LYN tyrosine kinase.
Winkelmann J.C.,et al.Blood 76:24-30(1990).
Jones S.S.,et al.Blood 76:31-35(1990).
Noguchi C.T.,et al.Blood 78:2548-2556(1991).
Ehrenman K.,et al.Exp. Hematol. 19:973-977(1991).
Nakamura Y.,et al.Science 257:1138-1141(1992).